相关实验视频
Updated: Jan 13, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
在接受胰岛素治疗的患者中,移动应用支持糖尿病管理的现实世界证据
Lena Roth1, Julian Stein1, Peter E H Schwarz1
1Department for Prevention and Care of Diabetes, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, tu-dresden.de.
Journal of diabetes research
|January 7, 2026
概括
移动糖尿病应用程序ESYSTA显著改善了血糖控制,HbA1c水平在六个月后降低了-0.59%,并持续长期. 现实世界的数据显示其在治疗糖尿病方面的有效性.
科学领域:
- 数字健康数字健康
- 糖尿病管理 糖尿病管理
- 现实世界的证据.
背景情况:
- 数字健康干预措施,如移动糖尿病应用程序,旨在改善血糖控制.
- 现实世界数据 (RWD) 提供了超越临床试验的长期疗效的见解.
研究的目的:
- 评估ESYSTA移动糖尿病应用程序在使用RWD增强血糖控制方面的有效性.
- 评估ESYSTA应用程序用户的长期HbA1c变化.
主要方法:
- 对475名ESYSTA用户进行了回顾性分析.
- 评估HbA1c在6,12和15个月的变化.
- 线性混合效应模型用于调整混因素.
主要成果:
- 6个月后HbA1c显著降低-0.59%,持续至15个月.
- 在基线HbA1c较高的用户中观察到更大的HbA1c降低.
- 75%的使用者在整个研究期间始终跟踪血糖.
结论:
- 移动糖尿病应用程序,如ESYSTA,在改善长期血糖控制方面表现出有效性.
- 现实世界的证据支持糖尿病数字健康干预措施的持续益处.
- 需要进行进一步的受控研究来证实发现并探索机制.
相关概念视频
Diabetes: Management and Pharmacotherapy
858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Insulin: Dosing Regimen and Adverse Effects
673
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
673
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581

